Ari Johnson

Ari Johnson is co-founder and CEO of Muso, a global health organization working to stop preventable deaths in the world’s poorest communities. He is an associate professor of medicine at University of California San Francisco Institute for Global Health Sciences and treats patients at San Francisco General Hospital.

Johnson has published peer-reviewed articles and essays in the fields of infectious disease, health systems design, socioeconomic determinants of health, AIDS, and migration. For his work at Muso, he is the co-recipient of the 2021 Charles Bronfman Prize, an annual award presented to a humanitarian under 50 whose innovative work, informed by Jewish values, has significantly improved the world.

Over the past fifteen years, Johnson has supported Muso to pursue a cure for delayed health care, one of the world's leading causes of death and inequity. Johnson supported Muso to design and build Proactive Community Case Management, a strategy for rapid, universal access to care. A recent study in BMJ Global Health documented how communities served by this proactive strategy have achieved and sustained a rate of child death lower than any country in Sub-Saharan Africa for five years running. Muso currently cares for 330,000 patients, and supports the governments of Mali and Côte d’Ivoire to redesign their national health systems to pursue universal, early access to care.